COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment.
Ann Clin Psychiatry
; 35(2): 118-130, 2023 05.
Article
in English
| MEDLINE | ID: covidwho-2301148
ABSTRACT
BACKGROUND:
Emerging literature supports the association between acute COVID-19 infection and neuropsychiatric complications. This article reviews the evidence for catatonia as a potential neuropsychiatric sequela of COVID-19 infection.METHODS:
PubMed was searched using the terms catatonia, severe acute respiratory syndrome coronavirus 2, and COVID-19. Articles were limited to those published in the English language between 2020 and 2022. Forty-five articles that specifically studied catatonia associated with acute COVID-19 infection were screened.RESULTS:
Overall, 30% of patients with severe COVID-19 infection developed psychiatric symptoms. We found 41 cases of COVID-19 and catatonia, with clinical presentations that varied in onset, duration, and severity. One death was reported in a case of catatonia. Cases were reported in patients with and without a known psychiatric history. Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments.CONCLUSIONS:
Greater recognition and treatment of catatonia in individuals with COVID-19 infection is warranted. Clinicians should be familiar with recognizing catatonia as a potential outcome of COVID-19 infection. Early detection and appropriate treatment are likely to lead to better outcomes.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Catatonia
/
Electroconvulsive Therapy
/
COVID-19
/
Mental Disorders
Type of study:
Case report
/
Observational study
/
Prognostic study
/
Reviews
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Ann Clin Psychiatry
Journal subject:
Psychiatry
Year:
2023
Document Type:
Article
Affiliation country:
Acp.0109
Similar
MEDLINE
...
LILACS
LIS